| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.50.5.1273 |
| P698 | PubMed publication ID | 9595974 |
| P50 | author | Per Soelberg Sørensen | Q12331359 |
| P2093 | author name string | M L Lee | |
| K Schreiber | |||
| B Wanscher | |||
| M Ravnborg | |||
| M Blinkenberg | |||
| C V Jensen | |||
| V A Larsen | |||
| H Kirsmeier | |||
| P433 | issue | 5 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| magnetic resonance imaging | Q161238 | ||
| P304 | page(s) | 1273-1281 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis | |
| P478 | volume | 50 |
| Q83232977 | 9 Human Immunoglobulins |
| Q55465940 | Adverse Effects of Immunoglobulin Therapy. |
| Q33733019 | Adverse effects of intravenous immunoglobulin therapy |
| Q33911894 | Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials |
| Q37971896 | Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis |
| Q34100103 | B cells and antibodies in CNS demyelinating disease |
| Q58196813 | Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies |
| Q35294158 | Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants? |
| Q31047410 | Childhood multiple sclerosis: a review |
| Q34590775 | Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. |
| Q30640097 | Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets |
| Q35891544 | Combination therapy for multiple sclerosis: the treatment strategy of the future? |
| Q48820330 | Correlations of brain MRI parameters to disability in multiple sclerosis |
| Q43049261 | Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences |
| Q36119226 | Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis |
| Q34129926 | Differentiation of multiple sclerosis subtypes: implications for treatment |
| Q39330225 | Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls |
| Q46318463 | How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis? |
| Q35805634 | Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis |
| Q48376416 | IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions |
| Q36602808 | IVIG therapy in neurological disorders of childhood |
| Q51777739 | IVIG trials in MS. Is albumin a placebo? |
| Q44230219 | Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis |
| Q36359691 | Intravenous immunoglobulin and multiple sclerosis |
| Q34574581 | Intravenous immunoglobulin in neurological disease: a specialist review. |
| Q33366800 | Intravenous immunoglobulin in neurological disorders: a mechanistic perspective |
| Q50749619 | Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. |
| Q36602782 | Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis |
| Q24247968 | Intravenous immunoglobulins for multiple sclerosis |
| Q52023443 | Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. |
| Q34750094 | MRI monitoring of MS in clinical trials |
| Q33660838 | Medications used in the treatment of multiple sclerosis. |
| Q91818544 | Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis |
| Q57725971 | Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients |
| Q34274227 | Multiple sclerosis in childhood and adolescence: clinical features and management |
| Q37001453 | Multiple sclerosis therapy: an update on recently finished trials |
| Q33327825 | Neuron-specific enolase antibodies in patients with sudden acquired retinal degeneration syndrome |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q30581459 | New therapeutic strategies in multiple sclerosis |
| Q50711021 | No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. |
| Q73800856 | Normal polyclonal immunoglobulins ('IVIg') inhibit microglial phagocytosis in vitro |
| Q58861268 | Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin |
| Q33798244 | Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis |
| Q40897021 | Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg"). |
| Q82915741 | Pediatric multiple sclerosis |
| Q73276229 | Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors |
| Q48203709 | Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes |
| Q78039549 | Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants |
| Q40821906 | Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis |
| Q34707921 | Primary progressive multiple sclerosis: increasing clarity but many unanswered questions |
| Q33678174 | Progress in determining the causes and treatment of multiple sclerosis |
| Q28363134 | Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? |
| Q75262477 | The effects of interferon-alpha2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis |
| Q73903947 | The immunomodulatory properties of in vitro immunoglobulins are dose-dependent |
| Q34268029 | The role of antigen presenting cells in multiple sclerosis |
| Q35057210 | The role of intravenous immunoglobulin in the treatment of multiple sclerosis |
| Q30585724 | The role of magnetic resonance in the assessment of multiple sclerosis. |
| Q47983767 | The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. |
| Q24629115 | Theiler's virus infection: a model for multiple sclerosis |
| Q33699351 | Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders |
| Q30592222 | What is new in the treatment of multiple sclerosis? |
| Q80953233 | [Immunomodulatory effects of intravenous immunoglobulins] |
| Q81581376 | [Intravenous immunoglobulins in chronic idiopathic myositis] |
| Q84367880 | [Intravenous immunoglobulins in multiple sclerosis. An update] |
| Q73507540 | [Therapeutic indications of intravenous immunoglobulins] |
| Q80257893 | [Use of i.v. immunoglobulins in neurology. Evidence-based consensus] |
Search more.